GlobalData on MSN
REGENXBIO to push for accelerated approval of DMD gene therapy
REGENXBIO touted data from the Phase III portion of a study that showed higher benefit that Elevidys.
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ...
Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic ...
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make ...
The closest-ever detailed look at a key enzyme inside the virus that causes COVID-19 could lead to more effective treatment ...
Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent AD ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which emphasizes the need to optimize gene delivery methods and monitor ...
Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results